drugset
drugset / Trial / NCT03726853

The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497

NCT03726853 ↗

Phase 2 Completed 220 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of CKD-497

Timeline

Start
2018-05-29
Primary completion
2019-03-21
Completion
2019-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-497 Unknown 200 mg —
Subject CKD-497 Unknown 300 mg —

Indications

respiratory tract infectious disorder